
# *nad* biosynthetic mutants of *Mycobacterium tuberculosis*: a tool to elucidate PZA action?

Essentiality of PZA Workshop May31-June1

# **Mechanisms of Action of PZA**



Y. Zhang, D. Mitchison. 2003. Int. J. Tuberc. Lung Dis. 7(1):6–21

# PZA increases NAD<sup>+</sup> content in rats

>Effects of dietary pyrazinamide, an antituberculosis agent, on the metabolism of tryptophan to niacin and of tryptophan to serotonin in rats.

Shibata K, Fukuwatari T, Sugimoto E. Biosci Biotechnol Biochem. 2001, 65:1339-46.


The administration of pyrazinamide significantly increased the metabolites, 3-hydroxyanthranilic acid and beyond, especially quinolinic acid, nicotinamide, N'-methylnicotinamide, and N1-methyl-4-pyridone-3-carboxamide. However, no difference in the upper metabolites of the tryptophan to niacin pathway. It is suggested from these results that the **action of pyrazinamide against tuberculosis is linked to the increase in turnover of NAD and to the increased content of NAD in the host cells.** 

>Pyridine nucleotide levels in liver of rats fed clofibrate- or pyrazinamide-containing diets. Shin M, Iwamoto N, Yamashita M, Sano K, Umezawa C. Biochem Pharmacol. 1998, 55:367-71.

The NAD<sup>+</sup>/NADH ratio remained unchanged with a 1% pyrazinamide diet. Hepatic quinolinate phosphoribosyltransferase (QAPRTase) activity was increased to 1.3 times that of the control animals in the pyrazinamide-fed rats, respectively, while hepatic aminocarboxymuconate-semialdehyde decarboxylase (ACMSDase) activity was decreased to 19% of that of the control animals. We conclude that these changes of enzyme activities may contribute to the increase of pyridine nucleotides in the liver of rats fed pyrazinamide.

➤ The effect of pyrazines on the metabolism of tryptophan and nicotinamide adenine dinucleotide in the rat. Evidence of the formation of a potent inhibitor of aminocarboxy-muconate-semialdehyde decarboxylase from pyrazinamide. Nasu S, Yamaguchi K, Sakakibara S, Imai H, Ueda I. Biochim Biophys Acta. 1981, 677:109-19.


# NAD<sup>+</sup> biosynthetic pathway




# Hypothesis

PZA can enter the NAD<sup>+</sup> salvage pathway as an analog of nicotinamide and alter the NAD<sup>+</sup> biosynthesis.

# NAD<sup>+</sup> salvage pathway



#### **PZA** in the NAD<sup>+</sup> salvage pathway



pyrazinoic acid mononucleotide POAMN


pyrazinoic acid adenine dinucleotide

POAAD

CONH<sub>2</sub> ÒН ÒН NH<sub>2</sub> Η O = PÔH OH

pyrazinamide adenine dinucleotide **PAD**<sup>+</sup>


# **NAD<sup>+</sup>** biosynthesis




#### Growth of $\Delta nadABC$ mutants in vitro

M. bovis  $\Delta nadABC$ 


M. tuberculosis  $\Delta nadABC$ 




#### *M. bovis* Δ*nadABC* pMV261::*pncA*<sup>TB</sup> growth in vitro




#### **NAD<sup>+</sup>** and **NADH** concentrations in $\Delta nadABC$ mutants




# CDC1551 ∆nadABC mutant in C57Bl/6 mice



# Ravenel *AnadABC* mutant in C57Bl/6 mice






- *M. bovis* Δ*nadABC* pMV361::*nadABC*
- *M. bovis*  $\Delta nadABC$  pMV261::*pncA*<sup>TB</sup>
- M. bovis  $\Delta$ nadABC

# NAD<sup>+</sup> biosynthesis in *M. tuberculosis* ∆*nadABC*

Aspartate nicotinamide pncA PZA  $\alpha$ -iminosuccinate nadA quinolinate nicotinate nadC pncB NAMN nadD deamido-NAD<sup>+</sup> nadE NAI

# NAD<sup>+</sup> and NADH concentrations in PZA-treated *M. tuberculosis*



*M. tuberculosis* H37Rv, grown in Middlebrook 7H9-OADC-Tylo (pH 6.0), was treated with PZA (500 mg/l) prior to NAD<sup>+</sup> and NADH extraction.

# Possible experiments to test if PZA disrupts NAD<sup>+</sup> biosynthesis

- Treat Nam-starved *M. tuberculosis ∆nadABC* with PZA and measure NAD<sup>+</sup> and NADH concentrations.
- Treat Nam-starved *M. tuberculosis ∆nadABC* with PZA and identified PZA metabolites by MS.
- Treat Nam-starved *M. tuberculosis*  $\Delta nadABC$  with labeled PZA and identified PZA metabolites.

• PZA and INH.